Growth factor modulation of melanoma growth stimulatory activity mRNA expression in human malignant melanoma cells correlates with cell growth

1989 ◽  
Vol 39 (4) ◽  
pp. 421-428 ◽  
Author(s):  
R. Bordoni ◽  
G. Thomas ◽  
A. Richmond
Keyword(s):  
Growth Factor ◽  
Cell Growth ◽  
Malignant Melanoma ◽  
Mrna Expression ◽  
Melanoma Cells ◽  
Human Malignant Melanoma ◽  
Stimulatory Activity ◽  
Melanoma Growth

scholarly journals Anti-oncogenic MicroRNA-203 Induces Senescence by Targeting E2F3 Protein in Human Melanoma Cells

2012 ◽  
Vol 287 (15) ◽  
pp. 11769-11777 ◽  
Author(s):  
Shunsuke Noguchi ◽  
Takashi Mori ◽  
Yusami Otsuka ◽  
Nami Yamada ◽  
Yuki Yasui ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Growth ◽  
Malignant Melanoma ◽  
Cell Cycle Arrest ◽  
Ectopic Expression ◽  
Melanoma Cells ◽  
Microrna Target ◽  
Human Malignant Melanoma ◽  
Cycle Arrest ◽  
Tissue Specimens

MicroRNAs regulate gene expression by repressing translation or directing sequence-specific degradation of their complementary mRNA. We recently reported that miR-203 is down-regulated, and its exogenous expression inhibits cell growth in canine oral malignant melanoma tissue specimens as well as in canine and human malignant melanoma cells. A microRNA target database predicted E2F3 and ZBP-89 as putative targets of microRNA-203 (miR-203). The expression levels of E2F3a, E2F3b, and ZBP-89 were markedly up-regulated in human malignant melanoma Mewo cells compared with those in human epidermal melanocytes. miR-203 significantly suppressed the luciferase activity of reporter plasmids containing the 3′-UTR sequence of either E2F3 or ZBP-89 complementary to miR-203. The ectopic expression of miR-203 in melanoma cells reduced the levels of E2F3a, E2F3b, and ZBP-89 protein expression. At the same time, miR-203 induced cell cycle arrest and senescence phenotypes, such as elevated expression of hypophosphorylated retinoblastoma and other markers for senescence. Silencing of E2F3, but not of ZBP-89, inhibited cell growth and induced cell cycle arrest and senescence. These results demonstrate a novel role for miR-203 as a tumor suppressor acting by inducing senescence in melanoma cells.

scholarly journals E3 ubiquitin ligase PARK2, an inhibitor of melanoma cell growth, is repressed by the oncogenic ERK1/2-ELK1 transcriptional axis

2020 ◽  
Vol 295 (47) ◽  
pp. 16058-16071
Author(s):  
Valentina Montagnani ◽  
Luisa Maresca ◽  
Alessandro Apollo ◽  
Sara Pepe ◽  
Ryan M. Carr ◽  
...  
Keyword(s):  
Cell Growth ◽  
Malignant Melanoma ◽  
Melanoma Cell ◽  
Ubiquitin Ligase ◽  
E3 Ubiquitin Ligase ◽  
Melanoma Cells ◽  
Mapk Signaling ◽  
Braf V600e ◽  
Promising Therapeutic Approach ◽  
Melanoma Growth

Malignant melanoma, the most aggressive form of skin cancer, is characterized by high prevalence of BRAF/NRAS mutations and hyperactivation of extracellular signal-regulated kinase 1 and 2 (ERK1/2), mitogen-activated protein kinases (MAPK), leading to uncontrolled melanoma growth. Efficacy of current targeted therapies against mutant BRAF or MEK1/2 have been hindered by existence of innate or development of acquired resistance. Therefore, a better understanding of the mechanisms controlled by MAPK pathway driving melanogenesis will help develop new treatment approaches targeting this oncogenic cascade. Here, we identify E3 ubiquitin ligase PARK2 as a direct target of ELK1, a known transcriptional effector of MAPK signaling in melanoma cells. We show that pharmacological inhibition of BRAF-V600E or ERK1/2 in melanoma cells increases PARK2 expression. PARK2 overexpression reduces melanoma cell growth in vitro and in vivo and induces apoptosis. Conversely, its genetic silencing increases melanoma cell proliferation and reduces cell death. Further, we demonstrate that ELK1 is required by the BRAF-ERK1/2 pathway to repress PARK2 expression and promoter activity in melanoma cells. Clinically, PARK2 is highly expressed in WT BRAF and NRAS melanomas, but it is expressed at low levels in melanomas carrying BRAF/NRAS mutations. Overall, our data provide new insights into the tumor suppressive role of PARK2 in malignant melanoma and uncover a novel mechanism for the negative regulation of PARK2 via the ERK1/2-ELK1 axis. These findings suggest that reactivation of PARK2 may be a promising therapeutic approach to counteract melanoma growth.

Genistein Enhances the Cisplatin-Induced Inhibition of Cell Growth and Apoptosis in Human Malignant Melanoma Cells

2003 ◽  
Vol 16 (5) ◽  
pp. 470-476 ◽  
Author(s):  
Shingo Tamura ◽  
Toshinori Bito ◽  
Masamitsu Ichihashi ◽  
Masato Ueda
Keyword(s):  
Cell Growth ◽  
Malignant Melanoma ◽  
Melanoma Cells ◽  
Human Malignant Melanoma

Preparation of a monoclonal antibody to a melanoma growth-stimulatory activity released into serum-free culture medium by Hs0294 malignant melanoma cells

1987 ◽  
Vol 34 (3) ◽  
pp. 169-185 ◽  
Author(s):  
David H. Lawson ◽  
H. Greg Thomas ◽  
Robert G. B. Roy ◽  
David S. Gordon ◽  
Rajender K. Chawla ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Malignant Melanoma ◽  
Culture Medium ◽  
Melanoma Cells ◽  
Serum Free ◽  
Stimulatory Activity ◽  
Melanoma Growth

scholarly journals Toxicogenomics of A375 human malignant melanoma cells treated with arbutin

2006 ◽  
Vol 14 (1) ◽  
pp. 87-105 ◽  
Author(s):  
Sun-Long Cheng ◽  
Rosa Huang Liu ◽  
Jin-Nan Sheu ◽  
Shui-Tein Chen ◽  
Supachok Sinchaikul ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Melanoma Cells ◽  
Human Malignant Melanoma
Sign in / Sign up

Export Citation Format

Share Document